Test of a new nose spray for nosebleeds in HHT
Part of Blood & lymphatic, Ear, nose & throat, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new nose spray (TOR-582) to reduce nosebleeds in people with HHT. If you have moderate nosebleeds, this treatment might help decrease how often and how long they last.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of HHT.
- You have moderate nosebleeds (at least 4 per week, lasting at least 60 minutes total).
- Your nosebleed pattern and any treatments you use for them have been stable for the past 3 months.
- You are willing to avoid starting other new treatments for nosebleeds during the study.
- You are not currently taking blood thinners (except low-dose aspirin) or certain other medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
This study looks at different management strategies for severe nosebleeds when the initial packing method has not worked for over 48 hours. It also measures the cost/benefit of these approaches to help improve care.
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
This trial tests an experimental pill, engasertib, to reduce frequent nosebleeds in adults with a rare blood vessel condition called hereditary hemorrhagic telangiectasia (HHT). Participation may help if you have moderate to severe nosebleeds and need iron or blood transfusions.
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
Hear when a new Epistaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.